Overview

Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance

Status:
Active, not recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

A number of strategies have been proposed to improve the outcome of ASCT. The three main strategies are to incorporate novel agents into the induction regimen, using maintenance therapy following ASCT and the final strategy is to enhance conditioning regimens. Investigators would like to explore all these three strategies in this study: Investigators propose to take patients who have had standard novel agent (bortezomib) based induction regimens into this study and then use a dose-adjusted combination of busulfan and melphalan as conditioning regimen and finally Investigators would like to incorporate lenalidomide maintenance post ASCT until disease progression.

Phase:

Phase 2

Details

Lead Sponsor:

University Health Network, Toronto

Collaborators:

Celgene Corporation
Otsuka Pharmaceutical Development & Commercialization, Inc.
Princess Margaret Hospital, Canada

Treatments:

Busulfan
Lenalidomide
Melphalan
Thalidomide